NCT05103423

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	BDB-001 Injection	Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
DRUG	Placebo	Multiple IV infusions of Placebo Injection diluted in sodium chloride
DRUG	Placebo	Multiple IV infusions of Placebo Injection diluted in sodium chloride

Timeline

• Start date: 2021-06-24
• Primary completion: 2023-07-07
• Completion: 2023-07-07
• First posted: 2021-11-02
• Last updated: 2024-03-26

Locations

15 sites across 1 country: China